Merck stock rises 55% in a year on strong post-Keytruda growth strategy.

Merck & Co. has gained 55% over the past year, driven by investor optimism about its strategy to offset revenue losses from Keytruda's patent expiry in 2028. The company has diversified its pipeline through acquisitions and partnerships with firms like Terns Pharma and Daiichi Sankyo. Analysts project that by 2030, new products could generate around $17.35 billion in revenue, potentially boosting Merck's valuation by 15% above current levels. Despite an expected revenue dip post-2028, Merck's proactive research and development efforts position it for steady growth and resilience in the pharmaceutical sector.